Now accepting Telehealth appointments. Schedule a virtual visit.

Myo-inositol Fertility Benefits: Does myo-inositol improve egg quality and IVF success rates?

 Myo-inositol Fertility Benefits

What is myo-inositol?

Myo-inositol is often used to improve egg quality in IVF, but only _some _infertility patients reap the myo-inositol egg quality benefits.

Myo-inositolused to be considered a vitamin within the vitamin B family but no longer has this designation. It is increasingly prescribed within the fertility field under the claim that it improves egg and embryo quality and, therefore, pregnancy rates in IVF. It is a so-called second messenger in signal transduction pathways and has been reported to be involved in the secretion of hormones by ovaries and some other endocrine glands. Its alleged effects have been especially highlighted in women with polycystic ovary syndrome (PCOS), where it is considered an insulin sensitizer, like metformin. Some studies have suggested that it reestablishes ovulation in a high percentage of anovulatory PCOS patients. At least one report in the literature suggests that supplementation with myo-inositol reduces the risk of gestational diabetes in pregnancy.

How is myo-inositol used in IVF cycles?

In female infertility, it has been suggested to reduce the amount of gonadotropin required for ovarian stimulation, improves egg numbers and quality and that high levels in amniotic fluid are associated with improved follicle stimulating hormone (FSH) signaling, oocyte maturation and embryo development.

Up to a dosage of 12 grams daily, myo-inositol appears to be well tolerated without significant side-effects, though nausea, fatigue, dizziness and insomnia have been reported. The most widely used dosage is 2 grams of myo-inositol in a 40:1 mixture with D-chiro-inositol in combination with 400 micrograms of folic acid twice a day. When supplementation should be initiated in association with IVF is unclear; but most reported studies initiated treatment 1-3 months before cycle start.

How does myo-inositol work?

Myo-inositol reduces androgen (male hormone levels). In hyper-androgenic PCOS patients, that may represent a significant benefit. In many other women with infertility, such as women with premature ovarian aging (POA, also called occult primary ovarian insufficiencyor oPOI) or in women with hypo-androgenic PCOS (H-PCOS), both conditions where women actually have abnormally low androgen levels, this hypo-androgenism may be exacerbated by myo-inositol supplementation.

CHR, therefore, does not recommend automatic myo-inositol supplementation since it may counteract androgen supplementation in women with POA/oPOI and H-PCOS, which at CHR is routine since ovaries must have normal testosterone levels within the ovarian micro-environment in order to produce good quality eggs at maximum numbers.

Who reaps myo-inositol fertility benefits?

In selected infertile women, especially in women with so-called classical PCOS phenotype, who demonstrate abnormally high testosterone levels in their blood, using myo-inositol supplements for fertility and pregnancy, therefore, appears indicated. CHR advises against routine supplementation in all infertile women, as the nutritional supplement industry, unfortunately, recommends without basis.

This is a part of the March 2019 CHR VOICE.

Norbert Gleicher, MD

Norbert Gleicher, MD, FACOG, FACS

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.

Follow on LinkedIn    

Watch his videos on YouTube    

 


We have helped women bring over
17,800 babies into the world.

DISCOVER YOUR TREATMENT OPTIONS

 

You Might Also Enjoy...

The Voice May 2022

April was a hectic month at the CHR because the deadline period for abstract submission to the Annual Meeting of the ASRM is always hectic.

The Voice April 2022

March was an unusually busy month at the CHR and not only clinically. CHR’s investigators saw several important papers published, with one in NATURE Medicine, in detail presented in the March issue of the VOICE, receiving unusual media attention

The Voice March 2022

With Spring per schedule knocking on the door, the mood in the world feels anything but spring-like. The deadly and cruel Russian war machine is already for weeks invading the independent country of Ukraine.

The Voice February 2022

In the shortest and traditionally coldest month of the year, we welcome you to the February issue of our monthly newsletter. Hopefully, history will show that we reached a point in the Covid-19 pandemic with more hope than at any time slot before.

The Voice December 2021

With the year 2021 coming to its end, most of us will agree that this was not a very good year to remember. We can only hope that 2022 will allow the world to return to more traditional living and working conditions, schooling, social interactions as well